EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antimicrobial Use, Regulatory Policies, and Resistance Challenges in Brazil: A Pharmacoepidemiological Overview with Implications for Comparable Settings

Maykon Jhuly Martins de Paiva, Sávia Denise Silva Carlotto Herrera, Renata Ferreira Diogo de Paiva, I Made Dwi Mertha Adnyana, Yslla Milla de Souza Alencar, Raísa Silva dos Santos, Emmeline de Sá Rocha, José Vinicius dos Anjos Nascimento, Flavio Ricardo Silva Sousa, Allana Nascimento Delgado Mota, Eduardo Saavedra Sánchez, Marco Aurélio Gondim Cordeiro und 11 weitere

Antibiotics · 16.11.2026 · 15 (11) · 1143

DOI: 10.3390/antibiotics15111143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibiotics, online erschienen am 16.11.2026. Verfasst von Maykon Jhuly Martins de Paiva und 22 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Antimicrobial resistance (AMR) is one of the most critical global public health challenges, particularly in low- and middle-income countries where antimicrobial consumption remains high. Brazil has historically exhibited elevated antimicrobial consumption in community settings, despite progressive regulatory interventions over the past decade. This article provides a pharmacoepidemiological overview of antimicrobial use, regulatory measures, and resistance-related challenges in Brazil, with implications for comparable settings.

Methods

A narrative review was conducted using PubMed/MEDLINE, Scopus, and SciELO, covering publications from January 2010 to December 2025 and restricted to English- and Portuguese-language sources. Official data from the National System for the Management of Controlled Products (SNGPC), ANVISA bulletins, BR-GLASS reports, and national AMR surveillance initiatives were also incorporated.

Results

Between 2014 and 2021, 355.7 million antimicrobial sales records were captured in the SNGPC (of 532.5 million controlled-product records; 2014 to November 2021). Amoxicillin (24.1%), azithromycin (12.2%), ciprofloxacin (9.4%), and cephalexin (7.7%) were the best-selling agents, and the top ten accounted for 76.5% of antimicrobial sales. DDD-based consumption increased by approximately 30% from 2014 to 2019, and 24 of 53 systemic antimicrobials (45%) were classified as WHO Watch, and Watch accounted for 45.5–49.9% of DDD-based consumption across regions in 2019. The COVID-19 pandemic was temporally associated with a 152% increase in azithromycin consumption (from 1.40 to 3.53 DDD/1000 inhabitants/day between February and July 2020). Carbapenem resistance in Klebsiella pneumoniae increased from 26% to 52% and remained elevated afterwards; this temporal association does not establish causality. Among Brazilian hospitals with adult intensive care units, fewer than 50% had a formal antimicrobial stewardship program.

Conclusions

Regulatory measures have strengthened prescription requirements and reduced non-prescription sales; however, their impact on inappropriate clinical use and resistance trends remains heterogeneous. Strengthening antimicrobial stewardship, improving microbiological diagnostic capacity, and integrating surveillance systems are essential priorities for mitigating AMR in Brazil and in comparable healthcare settings.

Zitieren

APA

Paiva, M. J. M. D., Herrera, S. D. S. C., Paiva, R. F. D. D., Adnyana, I. M. D. M., Alencar, Y. M. D. S., Santos, R. S. D., Rocha, E. D. S., Nascimento, J. V. D. A., Sousa, F. R. S., Mota, A. N. D., Sánchez, E. S., Cordeiro, M. A. G., Marçal, N. K. D. L., Arruda, R. L., Santos, T. B., Santos, T. T. D., Prado, S. M. B., Brito, M. M., Sena, L. W. P. D., …, & Vieira, J. L. F. (2026). Antimicrobial Use, Regulatory Policies, and Resistance Challenges in Brazil: A Pharmacoepidemiological Overview with Implications for Comparable Settings. Antibiotics, 15(11), 1143. https://doi.org/10.3390/antibiotics15111143

Vancouver

Paiva MJMD, Herrera SDSC, Paiva RFDD, Adnyana IMDM, Alencar YMDS, Santos RSD, et al. Antimicrobial Use, Regulatory Policies, and Resistance Challenges in Brazil: A Pharmacoepidemiological Overview with Implications for Comparable Settings. Antibiotics. 2026;15(11):1143. doi:10.3390/antibiotics15111143

BibTeX
@article{Paiva2026,
  author = {Paiva, Maykon Jhuly Martins de and Herrera, Sávia Denise Silva Carlotto and Paiva, Renata Ferreira Diogo de and Adnyana, I Made Dwi Mertha and Alencar, Yslla Milla de Souza and Santos, Raísa Silva dos and Rocha, Emmeline de Sá and Nascimento, José Vinicius dos Anjos and Sousa, Flavio Ricardo Silva and Mota, Allana Nascimento Delgado and Sánchez, Eduardo Saavedra and Cordeiro, Marco Aurélio Gondim and Marçal, Necy Kawamura de Lacerda and Arruda, Rejanne Lima and Santos, Talissa Bandeira and Santos, Taides Tavares dos and Prado, Silvia Minharro Barbosa and Brito, Márcio Miranda and Sena, Luann Wendel Pereira de and Sena, Maria Pantoja Moreira de and Chaves, Jorgete Carneiro and Ribeiro, Carolina Heitmann Mares Azevedo and Vieira, José Luiz Fernandes},
  title = {Antimicrobial Use, Regulatory Policies, and Resistance Challenges in Brazil: A Pharmacoepidemiological Overview with Implications for Comparable Settings},
  journal = {Antibiotics},
  year = {2026},
  volume = {15},
  number = {11},
  pages = {1143},
  doi = {10.3390/antibiotics15111143}
}
Kostenlos starten →